Page 66 - Read Online

Page 156 Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50

146. Maeda H, Nagata S, Wolfgang CD, Bratthauer GL, Bera TK, Pastan I. The T cell receptor gamma chain alternate reading frame
protein (TARP), a prostate-specific protein localized in mitochondria. J Biol Chem 2004;279:24561-8. DOI
147. Carlsson B, Tötterman TH, Essand M. Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen
TARP. Prostate 2004;61:161-70. DOI PubMed
148. Oh S, Terabe M, Pendleton CD, et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-
associated protein, TARP, lyse human breast cancer cells. Cancer Res 2004;64:2610-8. DOI
149. Kobayashi H, Nagato T, Oikawa K, et al. Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a
prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 2005;11:3869-78. DOI PubMed PMC
150. Epel M, Carmi I, Soueid-Baumgarten S, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell
receptor-like human recombinant antibodies. Eur J Immunol 2008;38:1706-20. DOI PubMed PMC
151. Hillerdal V, Nilsson B, Carlsson B, Eriksson F, Essand M. T cells engineered with a T cell receptor against the prostate antigen
+
TARP specifically kill HLA-A2 prostate and breast cancer cells. Proc Natl Acad Sci USA 2012;109:15877-81. DOI PubMed PMC
152. Hillerdal V, Boura VF, Björkelund H, Andersson K, Essand M. Avidity characterization of genetically engineered T-cells with novel
and established approaches. BMC Immunol 2016;17:23. DOI PubMed PMC
153. Bonte S, De Munter S, Goetgeluk G, et al. T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from
clinically relevant stem cell sources. Oncoimmunology 2020;9:1727078. DOI PubMed PMC
154. Vanhooren J, Derpoorter C, Depreter B, et al. TARP as antigen in cancer immunotherapy. Cancer Immunol Immunother
2021;70:3061-8. DOI PubMed PMC
155. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other
malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001;61:3760-9.
PubMed
156. Ochoa SV, Casas Z, Albarracín SL, Sutachan JJ, Torres YP. Therapeutic potential of TRPM8 channels in cancer treatment. Front
Pharmacol 2023;14:1098448. DOI PubMed PMC
157. Zhang L, Barritt GJ. TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr
Relat Cancer 2006;13:27-38. DOI
158. Bidaux G, Roudbaraki M, Merle C, et al. Evidence for specific TRPM8 expression in human prostate secretory epithelial cells:
functional androgen receptor requirement. Endocr Relat Cancer 2005;12:367-82. DOI
159. Valero M, Morenilla-Palao C, Belmonte C, Viana F. Pharmacological and functional properties of TRPM8 channels in prostate tumor
cells. Pflugers Arch 2011;461:99-114. DOI PubMed
160. Kiessling A, Füssel S, Schmitz M, et al. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-
associated protein trp-p8. Prostate 2003;56:270-9. DOI
161. Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (six-transmembrane epithelial antigen of the prostate 1-4) and their clinical
implications for prostate cancer. Cancers 2022;14:4034. DOI PubMed PMC
162. Jiao Z, Huang L, Sun J, et al. Six-transmembrane epithelial antigen of the prostate 1 expression promotes ovarian cancer metastasis
by aiding progression of epithelial-to-mesenchymal transition. Histochem Cell Biol 2020;154:215-30. DOI
163. Santos C, Socorro S, Maia CJ. STEAP1 (six transmembrane epithelial antigene of the prostate 1). 2009. Available from: https://
ubibliorum.ubi.pt/bitstream/10400.6/7635/1/STEAP1%20%28Six%20Transmembrane%20Epithelial%20Antigene.pdf [Last accessed
on 12 Apr 2024].
164. Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor
cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005;11:4545-52. DOI PubMed PMC
+
165. Alves PM, Faure O, Graff-Dubois S, et al. STEAP, a prostate tumor antigen, is a target of human CD8 T cells. Cancer Immunol
Immunother 2006;55:1515-23. DOI
166. Kobayashi H, Nagato T, Sato K, et al. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of
prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 2007;67:5498-504. DOI
167. Azumi M, Kobayashi H, Aoki N, et al. Six-transmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal
cell and bladder cancer. J Urol 2010;183:2036-44. DOI
168. Hayashi S, Kumai T, Matsuda Y, et al. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as
immunotherapeutic targets for lung cancer. J Transl Med 2011;9:191. DOI PubMed PMC
169. de la Luz Garcia-Hernandez M, Gray A, Hubby B, Kast WM. In vivo effects of vaccination with six-transmembrane epithelial
antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51. DOI PubMed
170. Kim S, Lee JB, Lee GK, Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific
antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 2009;69:938-48.
DOI
171. Challita-Eid PM, Morrison K, Etessami S, et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1
inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007;67:5798-805. DOI
172. Gati A, Lajmi N, Derouiche A, Marrakchi R, Chebil M, Benammar-Elgaaied A. NY-ESO-1 expression and immunogenicity in
prostate cancer patients. Tunis Med 2011;89:779-83. PubMed
173. Thomas R, Al-Khadairi G, Roelands J, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol
2018;9:947. DOI PubMed PMC
174. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun